RWM
ADMA icon

Rialto Wealth Management’s ADMA Biologics ADMA Stock Holding History

Rialto Wealth Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$118 Buy
13
+1
+8% +$16 ﹤0.01% 1652
2025
Q4 		$219 Hold
12
– – ﹤0.01% 1510
2025
Q3 		$176 Buy
12
+3
+33% +$51 ﹤0.01% 1515
2025
Q2 		$164 Buy
+9
New +$184 ﹤0.01% 1437

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Rialto Wealth Management's ADMA Position: Q1 2026 in Review

Rialto Wealth Management increased its ADMA Biologics (ADMA) stake by 8.3% in Q1 2026, buying an estimated $16 and bringing the position to 13 shares worth $118. The position accounts for ﹤0.01% of the portfolio, ranked #1652.

Rialto Wealth Management first reported a position in ADMA in Q2 2025 and has held it in 4 quarters since. The position peaked at $219 in Q4 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Rialto Wealth Management held 13 shares of ADMA Biologics worth $118 as of Q1 2026.
  • Rialto Wealth Management bought 1 ADMA Biologics share in Q1 2026, an estimated $16.
  • ADMA Biologics made up ﹤0.01% of Rialto Wealth Management's portfolio in Q1 2026, its #1652 holding.
  • Rialto Wealth Management first reported a position in ADMA Biologics in Q2 2025 and has held it in 4 quarters since.
  • Rialto Wealth Management's ADMA Biologics position peaked at $219 in Q4 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Rialto Wealth Management's 13F filing for Q1 2026, filed 14 May 2026.